Anti-IL18 ADCC Enhanced Antibody is an ADCC enhanced antibody produced by our Afuco™ platform. AFC-388CL is a humanised IgG1/kappa antibody which is directed against the soluble cytokine interleukin-18 (IL-18). AFC-388CL was generally well tolerated. The most common AEs were nasopharyngitis and headache, arising as frequently in the placebo as in the active drug groups; most AEs were mild to moderate and unrelated to dose level. There were no allergic, delayed-type hypersensitivity, or infusion-related reactions and the incidence of immunogenicity was low.
Figure 1 Mean plasma glucose levels revealed several apparent improvements in glucose control, as determined by reductions in FPG, in a number of patients dosed with placebo and doses of GSK1070806 up to Day 85.
McKie, E. A., Reid, J. L., Mistry, P. C., DeWall, S. L., Abberley, L., Ambery, P. D., & Gil-Extremera, B. (2016). A study to investigate the efficacy and safety of an anti-interleukin-18 monoclonal antibody in the treatment of type 2 diabetes mellitus. PLoS One, 11(3), e0150018.
Figure 2 With the exception of insulin and C-peptide at one time point (0.25 mg/kg vs placebo on Day 29), there were also no statistically significant effects of GSK1070806 doses on glucose, insulin and C-peptide weighted mean AUC(0–4 hours) over placebo on Days 29, 57, and 85.
McKie, E. A., Reid, J. L., Mistry, P. C., DeWall, S. L., Abberley, L., Ambery, P. D., & Gil-Extremera, B. (2016). A study to investigate the efficacy and safety of an anti-interleukin-18 monoclonal antibody in the treatment of type 2 diabetes mellitus. PLoS One, 11(3), e0150018.
Figure 3 Assessment of the mean change from baseline shows evidence of a reduction in HbA1c percent up to Day 85 with subjects dosed with GSK1070806 5 mg/kg compared with placebo, although the data are highly variable.
McKie, E. A., Reid, J. L., Mistry, P. C., DeWall, S. L., Abberley, L., Ambery, P. D., & Gil-Extremera, B. (2016). A study to investigate the efficacy and safety of an anti-interleukin-18 monoclonal antibody in the treatment of type 2 diabetes mellitus. PLoS One, 11(3), e0150018.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-1332z | Mouse Anti-IL18 Recombinant Antibody (clone 27G4) | WB, IF, ELISA | Mouse IgG2b |
HPAB-0064-YC | Human Anti-IL18 Recombinant Antibody (clone 2E1) | ELISA, RIA, IHC, FuncS, Neut | Human IgG |
HPAB-0065-YC | Human Anti-IL18 Recombinant Antibody (clone LT28) | ELISA, RIA, IHC, FuncS, Neut | Human IgG |
FAMAB-1199CQ | Mouse Anti-IL18 Recombinant Antibody (clone SAIC-24B-4) | Immuno-MRM, ELISA | Mouse IgG1 |
VS3-FY748 | Recombinant Rabbit Anti-IL18 Antibody (clone R02-8B2) | WB, IHC-P | Rabbit IgG |
There are currently no Customer reviews or questions for AFC-388CL. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.